nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Etoposide—sarcoma	0.0915	0.331	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—sarcoma	0.0535	0.193	CbGbCtD
Lenalidomide—ABCB1—Mitoxantrone—sarcoma	0.0479	0.173	CbGbCtD
Lenalidomide—ABCB1—Vincristine—sarcoma	0.0329	0.119	CbGbCtD
Lenalidomide—ABCB1—Etoposide—sarcoma	0.0302	0.109	CbGbCtD
Lenalidomide—TNFSF11—periosteum—sarcoma	0.0243	0.0974	CbGeAlD
Lenalidomide—ABCB1—Doxorubicin—sarcoma	0.0206	0.0744	CbGbCtD
Lenalidomide—TNFSF11—skull—sarcoma	0.02	0.0801	CbGeAlD
Lenalidomide—TNFSF11—leg—sarcoma	0.0194	0.0777	CbGeAlD
Lenalidomide—TNFSF11—forelimb—sarcoma	0.0192	0.0771	CbGeAlD
Lenalidomide—TNFSF11—hindlimb—sarcoma	0.0173	0.0694	CbGeAlD
Lenalidomide—TNFSF11—cartilage tissue—sarcoma	0.017	0.0683	CbGeAlD
Lenalidomide—TNFSF11—appendage—sarcoma	0.0149	0.0595	CbGeAlD
Lenalidomide—TNFSF11—Osteoblast Signaling—PDGFRB—sarcoma	0.013	0.0891	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoblast Signaling—PDGFRA—sarcoma	0.0128	0.0877	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MITF—sarcoma	0.00914	0.0627	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—MITF—sarcoma	0.00806	0.0553	CbGpPWpGaD
Lenalidomide—CDH5—endothelium—sarcoma	0.00675	0.027	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—PLCG1—sarcoma	0.00613	0.0421	CbGpPWpGaD
Lenalidomide—CDH5—mammary gland—sarcoma	0.00544	0.0218	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—FOXO1—sarcoma	0.00493	0.0339	CbGpPWpGaD
Lenalidomide—TNFSF11—embryo—sarcoma	0.00493	0.0198	CbGeAlD
Lenalidomide—TNFSF11—hematopoietic system—sarcoma	0.0044	0.0176	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—sarcoma	0.00424	0.017	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—FLT1—sarcoma	0.00399	0.0274	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PLCG1—sarcoma	0.00392	0.0269	CbGpPWpGaD
Lenalidomide—CDH5—myometrium—sarcoma	0.00386	0.0155	CbGeAlD
Lenalidomide—CDH5—embryo—sarcoma	0.00371	0.0149	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—KIT—sarcoma	0.0037	0.0254	CbGpPWpGaD
Lenalidomide—CDH5—seminal vesicle—sarcoma	0.00349	0.014	CbGeAlD
Lenalidomide—CDH5—hematopoietic system—sarcoma	0.00331	0.0133	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—VEGFC—sarcoma	0.00328	0.0225	CbGpPWpGaD
Lenalidomide—CDH5—connective tissue—sarcoma	0.00319	0.0128	CbGeAlD
Lenalidomide—PTGS2—periosteum—sarcoma	0.00316	0.0127	CbGeAlD
Lenalidomide—CDH5—S1P2 pathway—JUN—sarcoma	0.00313	0.0215	CbGpPWpGaD
Lenalidomide—TNFSF11—lymphoid tissue—sarcoma	0.0031	0.0124	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CTNNB1—sarcoma	0.00293	0.0201	CbGpPWpGaD
Lenalidomide—CDH5—smooth muscle tissue—sarcoma	0.00292	0.0117	CbGeAlD
Lenalidomide—TNFSF11—tendon—sarcoma	0.00291	0.0117	CbGeAlD
Lenalidomide—TNFSF11—bone marrow—sarcoma	0.00282	0.0113	CbGeAlD
Lenalidomide—CDH5—Adherens junctions interactions—CTNNB1—sarcoma	0.00277	0.019	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PLCG1—sarcoma	0.00273	0.0187	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—FLT1—sarcoma	0.00262	0.018	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PLCG1—sarcoma	0.00258	0.0177	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—JUN—sarcoma	0.00257	0.0177	CbGpPWpGaD
Lenalidomide—PTGS2—leg—sarcoma	0.00252	0.0101	CbGeAlD
Lenalidomide—CDH5—cardiac atrium—sarcoma	0.00252	0.0101	CbGeAlD
Lenalidomide—CDH5—uterus—sarcoma	0.0025	0.01	CbGeAlD
Lenalidomide—CRBN—myometrium—sarcoma	0.00245	0.00982	CbGeAlD
Lenalidomide—TNFSF11—testis—sarcoma	0.00241	0.00967	CbGeAlD
Lenalidomide—CRBN—embryo—sarcoma	0.00236	0.00944	CbGeAlD
Lenalidomide—CDH5—lymphoid tissue—sarcoma	0.00233	0.00934	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—KDR—sarcoma	0.0023	0.0158	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—JUN—sarcoma	0.00227	0.0156	CbGpPWpGaD
Lenalidomide—PTGS2—hindlimb—sarcoma	0.00225	0.00903	CbGeAlD
Lenalidomide—PTGS2—cartilage tissue—sarcoma	0.00222	0.00888	CbGeAlD
Lenalidomide—CRBN—seminal vesicle—sarcoma	0.00221	0.00887	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—sarcoma	0.00221	0.0152	CbGpPWpGaD
Lenalidomide—CDH5—tendon—sarcoma	0.00219	0.00878	CbGeAlD
Lenalidomide—CDH5—bone marrow—sarcoma	0.00212	0.00851	CbGeAlD
Lenalidomide—CRBN—hematopoietic system—sarcoma	0.0021	0.00843	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—sarcoma	0.00207	0.0142	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—SRC—sarcoma	0.00204	0.014	CbGpPWpGaD
Lenalidomide—PTGS2—appendage—sarcoma	0.00193	0.00774	CbGeAlD
Lenalidomide—CDH5—testis—sarcoma	0.00182	0.00727	CbGeAlD
Lenalidomide—TNFSF11—lymph node—sarcoma	0.00175	0.00701	CbGeAlD
Lenalidomide—CDH5—liver—sarcoma	0.00172	0.00687	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KDR—sarcoma	0.0016	0.011	CbGpPWpGaD
Lenalidomide—CRBN—cardiac atrium—sarcoma	0.0016	0.0064	CbGeAlD
Lenalidomide—CDH5—Cell-cell junction organization—CTNNB1—sarcoma	0.00159	0.0109	CbGpPWpGaD
Lenalidomide—CRBN—uterus—sarcoma	0.00159	0.00637	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—KDR—sarcoma	0.00151	0.0104	CbGpPWpGaD
Lenalidomide—CRBN—lymphoid tissue—sarcoma	0.00148	0.00593	CbGeAlD
Lenalidomide—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.00147	0.0101	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—sarcoma	0.00144	0.00988	CbGpPWpGaD
Lenalidomide—CRBN—tendon—sarcoma	0.00139	0.00558	CbGeAlD
Lenalidomide—CRBN—bone marrow—sarcoma	0.00135	0.0054	CbGeAlD
Lenalidomide—CDH5—lymph node—sarcoma	0.00132	0.00527	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—SRC—sarcoma	0.0013	0.00893	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—sarcoma	0.00127	0.0087	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CTNNB1—sarcoma	0.0012	0.00827	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.00118	0.00812	CbGpPWpGaD
Lenalidomide—PTGS2—endothelium—sarcoma	0.00117	0.00467	CbGeAlD
Lenalidomide—CRBN—testis—sarcoma	0.00115	0.00462	CbGeAlD
Lenalidomide—CRBN—liver—sarcoma	0.00109	0.00437	CbGeAlD
Lenalidomide—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.00104	0.00713	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CTNNB1—sarcoma	0.001	0.00688	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—CTNNB1—sarcoma	0.000946	0.00649	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—SRC—sarcoma	0.000906	0.00622	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—sarcoma	0.000882	0.00605	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—sarcoma	0.000871	0.00598	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—KDR—sarcoma	0.000861	0.00591	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—CTNNB1—sarcoma	0.000858	0.00589	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—SRC—sarcoma	0.000855	0.00587	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.000855	0.00587	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—sarcoma	0.000836	0.00335	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—sarcoma	0.000833	0.00572	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—sarcoma	0.000823	0.00565	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—SRC—sarcoma	0.000775	0.00532	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—sarcoma	0.00075	0.00515	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—sarcoma	0.000708	0.00486	CbGpPWpGaD
Lenalidomide—PTGS2—myometrium—sarcoma	0.000667	0.00267	CbGeAlD
Lenalidomide—PTGS2—embryo—sarcoma	0.000642	0.00257	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	0.000637	0.00438	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.000631	0.00433	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.000631	0.00433	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000623	0.00428	CbGpPWpGaD
Lenalidomide—PTGS2—seminal vesicle—sarcoma	0.000603	0.00241	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—sarcoma	0.000602	0.00413	CbGpPWpGaD
Lenalidomide—PTGS2—hematopoietic system—sarcoma	0.000573	0.0023	CbGeAlD
Lenalidomide—PTGS2—connective tissue—sarcoma	0.000552	0.00221	CbGeAlD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.000544	0.00374	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000522	0.00359	CbGpPWpGaD
Lenalidomide—PTGS2—smooth muscle tissue—sarcoma	0.000505	0.00202	CbGeAlD
Lenalidomide—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.000504	0.00346	CbGpPWpGaD
Lenalidomide—PTGS2—skin of body—sarcoma	0.000498	0.002	CbGeAlD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000496	0.0034	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000486	0.00334	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.000474	0.00326	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000463	0.00318	CbGpPWpGaD
Lenalidomide—PTGS2—uterus—sarcoma	0.000433	0.00173	CbGeAlD
Lenalidomide—ABCB1—myometrium—sarcoma	0.000413	0.00165	CbGeAlD
Lenalidomide—PTGS2—lymphoid tissue—sarcoma	0.000403	0.00162	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—TLE1—sarcoma	0.000403	0.00276	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.000398	0.00273	CbGpPWpGaD
Lenalidomide—ABCB1—embryo—sarcoma	0.000397	0.00159	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000387	0.00266	CbGpPWpGaD
Lenalidomide—PTGS2—tendon—sarcoma	0.000379	0.00152	CbGeAlD
Lenalidomide—ABCB1—seminal vesicle—sarcoma	0.000373	0.00149	CbGeAlD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000369	0.00253	CbGpPWpGaD
Lenalidomide—PTGS2—bone marrow—sarcoma	0.000367	0.00147	CbGeAlD
Lenalidomide—ABCB1—hematopoietic system—sarcoma	0.000354	0.00142	CbGeAlD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000345	0.00237	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.00034	0.00233	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFC—sarcoma	0.00034	0.00233	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000333	0.00229	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000304	0.00209	CbGpPWpGaD
Lenalidomide—PTGS2—liver—sarcoma	0.000297	0.00119	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—FLT1—sarcoma	0.000271	0.00186	CbGpPWpGaD
Lenalidomide—ABCB1—uterus—sarcoma	0.000268	0.00107	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—PLCG1—sarcoma	0.000267	0.00183	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000263	0.00181	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000257	0.00177	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCR4—sarcoma	0.000256	0.00176	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ATF1—sarcoma	0.000254	0.00174	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.00025	0.00172	CbGpPWpGaD
Lenalidomide—ABCB1—lymphoid tissue—sarcoma	0.00025	0.000999	CbGeAlD
Lenalidomide—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000241	0.00166	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.00024	0.00165	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000234	0.0016	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—PDGFRA—sarcoma	0.000232	0.00159	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000231	0.00159	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—sarcoma	0.000228	0.000912	CbGeAlD
Lenalidomide—ABCB1—bone marrow—sarcoma	0.000227	0.00091	CbGeAlD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.00022	0.00151	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000216	0.00148	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000215	0.00148	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.00021	0.00144	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1R—sarcoma	0.000199	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000199	0.00136	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000198	0.00136	CbGpPWpGaD
Lenalidomide—ABCB1—testis—sarcoma	0.000194	0.000778	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—FOXO1—sarcoma	0.000189	0.0013	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDGFRB—sarcoma	0.000189	0.0013	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDGFRA—sarcoma	0.000186	0.00128	CbGpPWpGaD
Lenalidomide—ABCB1—liver—sarcoma	0.000184	0.000736	CbGeAlD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000169	0.00116	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	0.000166	0.00114	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000161	0.00111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KDR—sarcoma	0.000157	0.00108	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	0.000145	0.000995	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KIT—sarcoma	0.000144	0.00099	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	0.000143	0.000979	CbGpPWpGaD
Lenalidomide—Headache—Thiotepa—sarcoma	0.000142	0.000434	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000142	0.000434	CcSEcCtD
Lenalidomide—Rash—Dactinomycin—sarcoma	0.000142	0.000433	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	0.000142	0.000975	CbGpPWpGaD
Lenalidomide—Decreased appetite—Etoposide—sarcoma	0.000142	0.000432	CcSEcCtD
Lenalidomide—Pancytopenia—Doxorubicin—sarcoma	0.000141	0.000431	CcSEcCtD
Lenalidomide—Renal failure—Epirubicin—sarcoma	0.000141	0.00043	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Etoposide—sarcoma	0.000141	0.00043	CcSEcCtD
Lenalidomide—ABCB1—lymph node—sarcoma	0.000141	0.000564	CbGeAlD
Lenalidomide—Asthenia—Mitoxantrone—sarcoma	0.000141	0.000429	CcSEcCtD
Lenalidomide—Fatigue—Etoposide—sarcoma	0.000141	0.000429	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Epirubicin—sarcoma	0.000141	0.000429	CcSEcCtD
Lenalidomide—Stomatitis—Epirubicin—sarcoma	0.00014	0.000426	CcSEcCtD
Lenalidomide—Constipation—Etoposide—sarcoma	0.00014	0.000425	CcSEcCtD
Lenalidomide—Pain—Etoposide—sarcoma	0.00014	0.000425	CcSEcCtD
Lenalidomide—Conjunctivitis—Epirubicin—sarcoma	0.000139	0.000425	CcSEcCtD
Lenalidomide—Urinary tract infection—Epirubicin—sarcoma	0.000139	0.000425	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—sarcoma	0.000139	0.000424	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—sarcoma	0.000139	0.000424	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000138	0.000422	CcSEcCtD
Lenalidomide—Diarrhoea—Vincristine—sarcoma	0.000138	0.00042	CcSEcCtD
Lenalidomide—Sweating—Epirubicin—sarcoma	0.000138	0.000419	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—sarcoma	0.000138	0.000419	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CREB1—sarcoma	0.000137	0.000943	CbGpPWpGaD
Lenalidomide—Haematuria—Epirubicin—sarcoma	0.000137	0.000417	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—sarcoma	0.000136	0.000414	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Epirubicin—sarcoma	0.000136	0.000414	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—sarcoma	0.000135	0.000413	CcSEcCtD
Lenalidomide—Epistaxis—Epirubicin—sarcoma	0.000135	0.000412	CcSEcCtD
Lenalidomide—Nausea—Thiotepa—sarcoma	0.000135	0.000411	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—sarcoma	0.000135	0.000411	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—sarcoma	0.000135	0.00041	CcSEcCtD
Lenalidomide—Feeling abnormal—Etoposide—sarcoma	0.000134	0.00041	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—sarcoma	0.000134	0.000409	CcSEcCtD
Lenalidomide—Diarrhoea—Mitoxantrone—sarcoma	0.000134	0.000409	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—sarcoma	0.000134	0.000408	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—sarcoma	0.000134	0.000408	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—sarcoma	0.000133	0.000407	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Etoposide—sarcoma	0.000133	0.000407	CcSEcCtD
Lenalidomide—Dizziness—Vincristine—sarcoma	0.000133	0.000406	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—sarcoma	0.000133	0.000912	CbGpPWpGaD
Lenalidomide—Infestation NOS—Doxorubicin—sarcoma	0.000133	0.000405	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—sarcoma	0.000133	0.000405	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000132	0.000401	CcSEcCtD
Lenalidomide—Bradycardia—Epirubicin—sarcoma	0.000131	0.0004	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—sarcoma	0.00013	0.000398	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—sarcoma	0.00013	0.000397	CcSEcCtD
Lenalidomide—Urticaria—Etoposide—sarcoma	0.00013	0.000395	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—sarcoma	0.000129	0.000889	CbGpPWpGaD
Lenalidomide—Haemoglobin—Epirubicin—sarcoma	0.000129	0.000395	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—sarcoma	0.000129	0.000394	CcSEcCtD
Lenalidomide—Rhinitis—Epirubicin—sarcoma	0.000129	0.000394	CcSEcCtD
Lenalidomide—Body temperature increased—Etoposide—sarcoma	0.000129	0.000393	CcSEcCtD
Lenalidomide—Abdominal pain—Etoposide—sarcoma	0.000129	0.000393	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—sarcoma	0.000129	0.000393	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—sarcoma	0.000129	0.000393	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—sarcoma	0.000129	0.000393	CcSEcCtD
Lenalidomide—Hepatitis—Epirubicin—sarcoma	0.000129	0.000393	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—sarcoma	0.000128	0.000391	CcSEcCtD
Lenalidomide—Vomiting—Vincristine—sarcoma	0.000128	0.00039	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—sarcoma	0.000128	0.00039	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—sarcoma	0.000127	0.000388	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—sarcoma	0.000127	0.000388	CcSEcCtD
Lenalidomide—Rash—Vincristine—sarcoma	0.000127	0.000387	CcSEcCtD
Lenalidomide—Dermatitis—Vincristine—sarcoma	0.000127	0.000387	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—sarcoma	0.000127	0.000387	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—sarcoma	0.000127	0.000386	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—sarcoma	0.000127	0.000386	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—sarcoma	0.000127	0.000868	CbGpPWpGaD
Lenalidomide—Urethral disorder—Epirubicin—sarcoma	0.000126	0.000385	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—sarcoma	0.000126	0.000866	CbGpPWpGaD
Lenalidomide—Headache—Vincristine—sarcoma	0.000126	0.000385	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—sarcoma	0.000126	0.000383	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—sarcoma	0.000125	0.000382	CcSEcCtD
Lenalidomide—Vomiting—Mitoxantrone—sarcoma	0.000125	0.00038	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—sarcoma	0.000125	0.00038	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000124	0.000852	CbGpPWpGaD
Lenalidomide—Visual impairment—Epirubicin—sarcoma	0.000124	0.000378	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—sarcoma	0.000124	0.000378	CcSEcCtD
Lenalidomide—Rash—Mitoxantrone—sarcoma	0.000124	0.000377	CcSEcCtD
Lenalidomide—Dermatitis—Mitoxantrone—sarcoma	0.000124	0.000377	CcSEcCtD
Lenalidomide—Headache—Mitoxantrone—sarcoma	0.000123	0.000375	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	0.000123	0.000843	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Epirubicin—sarcoma	0.000122	0.000371	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—sarcoma	0.000121	0.00037	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—sarcoma	0.00012	0.000367	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—sarcoma	0.00012	0.000367	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—sarcoma	0.00012	0.000366	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—sarcoma	0.00012	0.000365	CcSEcCtD
Lenalidomide—Nausea—Vincristine—sarcoma	0.00012	0.000365	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—sarcoma	0.00012	0.000364	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—sarcoma	0.00012	0.000364	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—sarcoma	0.000119	0.000364	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—sarcoma	0.000119	0.000363	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—sarcoma	0.000119	0.000363	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000119	0.000818	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Doxorubicin—sarcoma	0.000119	0.000361	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—sarcoma	0.000118	0.00036	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—sarcoma	0.000118	0.000359	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—sarcoma	0.000117	0.000358	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—sarcoma	0.000117	0.000357	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—sarcoma	0.000117	0.000357	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—sarcoma	0.000117	0.000356	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—sarcoma	0.000117	0.000356	CcSEcCtD
Lenalidomide—Nausea—Mitoxantrone—sarcoma	0.000117	0.000355	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—sarcoma	0.000116	0.000355	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—sarcoma	0.000116	0.000354	CcSEcCtD
Lenalidomide—Chills—Epirubicin—sarcoma	0.000116	0.000352	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—sarcoma	0.000115	0.000352	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—sarcoma	0.000115	0.000351	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—sarcoma	0.000115	0.00035	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000114	0.000785	CbGpPWpGaD
Lenalidomide—Alopecia—Epirubicin—sarcoma	0.000114	0.000347	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MDM2—sarcoma	0.000114	0.00078	CbGpPWpGaD
Lenalidomide—Mental disorder—Epirubicin—sarcoma	0.000113	0.000344	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—sarcoma	0.000113	0.000343	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—sarcoma	0.000112	0.000342	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—sarcoma	0.000112	0.000342	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—sarcoma	0.000112	0.00034	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—sarcoma	0.000111	0.000339	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—sarcoma	0.000111	0.000339	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—sarcoma	0.000111	0.000337	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—sarcoma	0.000111	0.000337	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—sarcoma	0.00011	0.000337	CcSEcCtD
Lenalidomide—Tension—Epirubicin—sarcoma	0.00011	0.000335	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—sarcoma	0.00011	0.000335	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—sarcoma	0.000109	0.000332	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—sarcoma	0.000108	0.000331	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—sarcoma	0.000108	0.00033	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—sarcoma	0.000108	0.000329	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—sarcoma	0.000108	0.000329	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—sarcoma	0.000108	0.000328	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—sarcoma	0.000108	0.000738	CbGpPWpGaD
Lenalidomide—Mediastinal disorder—Doxorubicin—sarcoma	0.000107	0.000327	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—sarcoma	0.000107	0.000326	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—sarcoma	0.000106	0.000324	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—sarcoma	0.000106	0.000322	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—sarcoma	0.000105	0.000321	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—sarcoma	0.000104	0.000318	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	0.000104	0.000716	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Epirubicin—sarcoma	0.000104	0.000317	CcSEcCtD
Lenalidomide—Vomiting—Etoposide—sarcoma	0.000104	0.000316	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—sarcoma	0.000104	0.000316	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—sarcoma	0.000104	0.000316	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—sarcoma	0.000104	0.000316	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—sarcoma	0.000103	0.000314	CcSEcCtD
Lenalidomide—Rash—Etoposide—sarcoma	0.000103	0.000314	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—sarcoma	0.000103	0.000313	CcSEcCtD
Lenalidomide—Headache—Etoposide—sarcoma	0.000102	0.000312	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—sarcoma	0.000102	0.000312	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—sarcoma	0.000102	0.00031	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—sarcoma	0.000102	0.00031	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL2—sarcoma	0.000102	0.000697	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—sarcoma	0.000101	0.000695	CbGpPWpGaD
Lenalidomide—Malaise—Epirubicin—sarcoma	0.000101	0.000308	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—sarcoma	0.000101	0.000307	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—sarcoma	0.000101	0.000307	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—sarcoma	0.000101	0.000306	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—sarcoma	0.0001	0.000306	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—sarcoma	0.0001	0.000306	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—sarcoma	9.97e-05	0.000304	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—sarcoma	9.91e-05	0.000302	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—sarcoma	9.9e-05	0.00068	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—sarcoma	9.9e-05	0.000679	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JUN—sarcoma	9.88e-05	0.000678	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	9.86e-05	0.000677	CbGpPWpGaD
Lenalidomide—Loss of consciousness—Epirubicin—sarcoma	9.85e-05	0.0003	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—sarcoma	9.8e-05	0.000673	CbGpPWpGaD
Lenalidomide—Cough—Epirubicin—sarcoma	9.78e-05	0.000298	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—sarcoma	9.78e-05	0.000298	CcSEcCtD
Lenalidomide—Nausea—Etoposide—sarcoma	9.69e-05	0.000296	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—sarcoma	9.68e-05	0.000295	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—sarcoma	9.62e-05	0.000293	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—sarcoma	9.59e-05	0.000292	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—sarcoma	9.54e-05	0.000291	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—sarcoma	9.54e-05	0.000291	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—sarcoma	9.54e-05	0.000291	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—sarcoma	9.53e-05	0.000291	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—sarcoma	9.51e-05	0.00029	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	9.48e-05	0.000289	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—sarcoma	9.43e-05	0.000287	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—sarcoma	9.35e-05	0.000285	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—sarcoma	9.33e-05	0.000285	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—sarcoma	9.32e-05	0.000284	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—sarcoma	9.3e-05	0.000284	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—sarcoma	9.28e-05	0.000283	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—sarcoma	9.22e-05	0.000281	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—sarcoma	9.17e-05	0.000279	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—sarcoma	9.15e-05	0.000279	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—sarcoma	9.12e-05	0.000278	CcSEcCtD
Lenalidomide—Infection—Epirubicin—sarcoma	9.09e-05	0.000277	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—sarcoma	9.05e-05	0.000276	CcSEcCtD
Lenalidomide—Shock—Epirubicin—sarcoma	9e-05	0.000274	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—sarcoma	8.97e-05	0.000273	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—sarcoma	8.96e-05	0.000273	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—sarcoma	8.95e-05	0.000273	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—sarcoma	8.93e-05	0.000272	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—sarcoma	8.89e-05	0.000271	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SRC—sarcoma	8.86e-05	0.000608	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Epirubicin—sarcoma	8.84e-05	0.00027	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—sarcoma	8.83e-05	0.000269	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—sarcoma	8.83e-05	0.000269	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—sarcoma	8.83e-05	0.000269	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—sarcoma	8.8e-05	0.000268	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	8.77e-05	0.000267	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—sarcoma	8.72e-05	0.000266	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—sarcoma	8.72e-05	0.000266	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—sarcoma	8.64e-05	0.000263	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—sarcoma	8.63e-05	0.000592	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	8.59e-05	0.000589	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	8.57e-05	0.000588	CbGpPWpGaD
Lenalidomide—Hypotension—Epirubicin—sarcoma	8.55e-05	0.000261	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—sarcoma	8.54e-05	0.00026	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NRAS—sarcoma	8.52e-05	0.000585	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	8.5e-05	0.000584	CbGpPWpGaD
Lenalidomide—Oedema—Doxorubicin—sarcoma	8.47e-05	0.000258	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	8.45e-05	0.00058	CbGpPWpGaD
Lenalidomide—Infection—Doxorubicin—sarcoma	8.41e-05	0.000256	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—sarcoma	8.34e-05	0.000254	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—sarcoma	8.33e-05	0.000254	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—sarcoma	8.31e-05	0.000571	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Doxorubicin—sarcoma	8.3e-05	0.000253	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—sarcoma	8.29e-05	0.000253	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—sarcoma	8.27e-05	0.000252	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—sarcoma	8.26e-05	0.000252	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—sarcoma	8.22e-05	0.000251	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—sarcoma	8.21e-05	0.00025	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—sarcoma	8.18e-05	0.000249	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—sarcoma	8.16e-05	0.000249	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—sarcoma	8.13e-05	0.000248	CcSEcCtD
Lenalidomide—Anorexia—Doxorubicin—sarcoma	8.07e-05	0.000246	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—sarcoma	8.05e-05	0.000245	CcSEcCtD
Lenalidomide—Decreased appetite—Epirubicin—sarcoma	7.95e-05	0.000242	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MYC—sarcoma	7.94e-05	0.000545	CbGpPWpGaD
Lenalidomide—Hypotension—Doxorubicin—sarcoma	7.91e-05	0.000241	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—sarcoma	7.9e-05	0.000241	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—sarcoma	7.89e-05	0.00024	CcSEcCtD
Lenalidomide—Pain—Epirubicin—sarcoma	7.82e-05	0.000238	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—sarcoma	7.82e-05	0.000238	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EGFR—sarcoma	7.77e-05	0.000533	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TLE1—sarcoma	7.75e-05	0.000532	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—sarcoma	7.71e-05	0.000235	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	7.69e-05	0.000528	CbGpPWpGaD
Lenalidomide—Insomnia—Doxorubicin—sarcoma	7.66e-05	0.000233	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—sarcoma	7.6e-05	0.000232	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—sarcoma	7.55e-05	0.00023	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—sarcoma	7.54e-05	0.00023	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—sarcoma	7.53e-05	0.000229	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	7.49e-05	0.000514	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Epirubicin—sarcoma	7.48e-05	0.000228	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—sarcoma	7.45e-05	0.000227	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—sarcoma	7.36e-05	0.000224	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KRAS—sarcoma	7.34e-05	0.000503	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—sarcoma	7.31e-05	0.000223	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—sarcoma	7.3e-05	0.000222	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—sarcoma	7.27e-05	0.000222	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—sarcoma	7.24e-05	0.000221	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—sarcoma	7.24e-05	0.000221	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—sarcoma	7.23e-05	0.00022	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—sarcoma	7.23e-05	0.00022	CcSEcCtD
Lenalidomide—PTGS2—Disease—NPM1—sarcoma	6.99e-05	0.00048	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	6.99e-05	0.00048	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—sarcoma	6.98e-05	0.000213	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—sarcoma	6.92e-05	0.000211	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	6.89e-05	0.000473	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—sarcoma	6.74e-05	0.000205	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	6.74e-05	0.000462	CbGpPWpGaD
Lenalidomide—Urticaria—Doxorubicin—sarcoma	6.72e-05	0.000205	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—sarcoma	6.69e-05	0.000204	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—sarcoma	6.69e-05	0.000204	CcSEcCtD
Lenalidomide—Asthenia—Epirubicin—sarcoma	6.56e-05	0.0002	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—sarcoma	6.52e-05	0.000447	CbGpPWpGaD
Lenalidomide—Pruritus—Epirubicin—sarcoma	6.47e-05	0.000197	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	6.36e-05	0.000437	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—sarcoma	6.26e-05	0.000191	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—sarcoma	6.24e-05	0.00019	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HRAS—sarcoma	6.24e-05	0.000428	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.09e-05	0.000418	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.07e-05	0.000417	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—sarcoma	6.07e-05	0.000185	CcSEcCtD
Lenalidomide—PTGS2—Disease—ENO2—sarcoma	6.06e-05	0.000416	CbGpPWpGaD
Lenalidomide—Dizziness—Epirubicin—sarcoma	6.05e-05	0.000184	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.03e-05	0.000414	CbGpPWpGaD
Lenalidomide—Pruritus—Doxorubicin—sarcoma	5.99e-05	0.000183	CcSEcCtD
Lenalidomide—Vomiting—Epirubicin—sarcoma	5.82e-05	0.000177	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—sarcoma	5.79e-05	0.000177	CcSEcCtD
Lenalidomide—Rash—Epirubicin—sarcoma	5.77e-05	0.000176	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—sarcoma	5.76e-05	0.000176	CcSEcCtD
Lenalidomide—Headache—Epirubicin—sarcoma	5.73e-05	0.000175	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.66e-05	0.000388	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—sarcoma	5.6e-05	0.000171	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	5.45e-05	0.000374	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—sarcoma	5.43e-05	0.000166	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—sarcoma	5.38e-05	0.000164	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—sarcoma	5.34e-05	0.000163	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—sarcoma	5.33e-05	0.000163	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.31e-05	0.000364	CbGpPWpGaD
Lenalidomide—Headache—Doxorubicin—sarcoma	5.3e-05	0.000162	CcSEcCtD
Lenalidomide—PTGS2—Disease—PLCG1—sarcoma	5.14e-05	0.000353	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO2—sarcoma	5.07e-05	0.000348	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HBA1—sarcoma	5.04e-05	0.000346	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—sarcoma	5.03e-05	0.000153	CcSEcCtD
Lenalidomide—PTGS2—Disease—CXCR4—sarcoma	4.94e-05	0.000339	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.88e-05	0.000335	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	4.78e-05	0.000328	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.51e-05	0.00031	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLCG1—sarcoma	4.31e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.01e-05	0.000275	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FOXO1—sarcoma	3.65e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFRB—sarcoma	3.64e-05	0.00025	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO2—sarcoma	3.6e-05	0.000247	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFRA—sarcoma	3.58e-05	0.000246	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HBA1—sarcoma	3.57e-05	0.000245	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLCG1—sarcoma	3.05e-05	0.000209	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KIT—sarcoma	2.78e-05	0.000191	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CREB1—sarcoma	2.65e-05	0.000182	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—sarcoma	2.19e-05	0.00015	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—sarcoma	1.89e-05	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SRC—sarcoma	1.71e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—sarcoma	1.64e-05	0.000113	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—sarcoma	1.53e-05	0.000105	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—sarcoma	1.5e-05	0.000103	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—sarcoma	1.41e-05	9.7e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—sarcoma	1.2e-05	8.24e-05	CbGpPWpGaD
